Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Tuberculosis Diagnostics and Treatment Market Analysis & Trends 2017 - Therapeutics, Diagnosis Forecast to 2025: Demand for Xpert MTB/RI in the Tuberculosis Diagnostics Landscape - Research and Markets

This image opens in the lightbox

News provided by

Research and Markets

14 Feb, 2017, 18:10 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, Feb 14, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Tuberculosis Diagnostics and Treatment Market Analysis & Trends- Therapeutics, Diagnosis - Forecast to 2025" report to their offering.

The Global Tuberculosis Diagnostics and Treatments Market is poised to grow at a CAGR of around 4.2% from 2015 to 2025

Some of the prominent trends that the market is Technologies that may replace smear microscopy continue to expand, Major investments in basic research related to Mycobaterium tuberculosis diagnosis, Demand for Xpert MTB/RI in the tuberculosis diagnostics landscape and Potential Market in Most of the Emerging Nations of the World.

Based on Therapeutics the market is categorized into Tuberculosis Drugs (First Line) and Tuberculosis Drugs (Second Line). The Tuberculosis Drugs (First Line) segment is Isoniazid (INH), Rifampin (RIF), Ethambutol (EMB) and Pyrazinamide (PZA). Tuberculosis Drugs (Second Line) segment is further represented as Aminoglycosides, Fluoroquinolones, Polypeptides, Thioamides, Cycloserine, p-Aminosalicylic Acid and Other Drugs.

Based on Diagnosis the market is categorized into Skin Testing and Laboratory Testing. The Laboratory Testing segment is further categorized into Adenosine Deaminas, Nucleic Acid Amplification Tests (NAAT), Interferon Gamma Release Assay, Antibody/Antigen Detection, Culture-Based Systems, Non-Culture Methods, Chest X-rays and computer-aided diagnosis, Biomarkers for active or latent TB, Serodiagnostic assays, Microscopy and associated tools, Cytokine detection assay, Smear Microscopy and Drug Susceptibility Testing (DST).

This industry report analyzes the global markets for Tuberculosis Diagnostics across all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.

Key Topics Covered:

1 Market Outline

1.1 Research Methodology

1.1.1 Research Approach & Sources

1.2 Market Trends

1.3 Regulatory Factors

1.4 End User Analysis

1.5 Application Analysis

1.6 Strategic Benchmarking

1.7 Opportunity Analysis

2 Executive Summary

3 Market Overview

3.1 Current Trends

3.1.1 Technologies that may replace smear microscopy continues to expand

3.1.2 Major investments in basic research related to Mycobacterium tuberculosis diagnosis

3.1.3 Demand for Xpert MTB/RI in the tuberculosis diagnostics landscape

3.1.4 Potential Market in Most of the Emerging Nations of the World

3.2 Drivers

3.3 Constraints

3.4 Industry Attractiveness

4 Tuberculosis Diagnostics and Treatments Market, By Therapeutics

4.1 Tuberculosis Drugs (First Line)

4.1.1.1 Isoniazid (INH)

4.1.1.2 Rifampin (RIF)

4.1.1.3 Ethambutol (EMB) 

4.1.1.4 Pyrazinamide (PZA)

4.2 Tuberculosis Drugs (Second Line)

4.2.1.1 Aminoglycosides 

4.2.1.2 Fluoroquinolones 

4.2.1.3 Polypeptides 

4.2.1.4 Thioamides 

4.2.1.5 Cycloserine 

4.2.1.6 p-Aminosalicylic Acid

4.2.1.7 Other Drugs

5 Tuberculosis Diagnostics and Treatments Market, By Diagnosis

5.1 Skin Testing 

5.2 Laboratory Testing 

5.2.1.1 Adenosine Deaminase

5.2.1.2 Nucleic Acid Amplification Tests (NAAT)

5.2.1.3 Interferon Gamma Release Assay

5.2.1.4 Antibody/Antigen Detection

5.2.1.5 Culture-Based Systems

5.2.1.6 Non-Culture Methods

5.2.1.7 Chest X-rays and computer-aided diagnosis

5.2.1.8 Biomarkers for active or latent TB

5.2.1.19 Serodiagnostic assays

5.2.1.10 Microscopy and associated tools

5.2.1.11 Cytokine detection assay

5.2.1.12 Smear Microscopy

5.2.1.13 Drug Susceptibility Testing (DST)

6 Tuberculosis Diagnostics and Treatments Market, By Geography 

7 Key Player Activities

7.1 Acquisitions & Mergers

7.2 Agreements, Partnerships, Collaborations and Joint Ventures

7.3 Product Launch & Expansions

7.4 Other Activities

8 Leading Companies

8.1 Cepheid Inc

8.2 Becton Dickinson

8.3 Hain LifeSciences

8.4 Abbott Laboratories,

8.5 Alere, Inc

8.6 F. Hoffmann-La Roche AG

8.7 Hologic Corporation

8.8 bioMérieux SA

8.9 Sanofi

8.10 QIAGEN

8.11 Akonni Biosystems, Inc.

8.12 Epistem Holdings Plc

8.13 Gen-Probe Inc.

8.14 EIKEN Chemical

8.15 Thermo Fisher Scientific, Inc

For more information about this report visit http://www.researchandmarkets.com/research/s4rkm8/global

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.